Quince Therapeutics Announces Major Clinical and Corporate Milestones Alongside Q2 2025 Financial Results Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to harnessing a patient’s own biology for the treatment of rare and underserved diseases, has delivered a…
Enanta Pharmaceuticals Reports Fiscal Third Quarter 2025 Results and Provides Pipeline Progress Update Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule drugs for viral infections and immunological diseases, today announced…
Equillium Secures Up to $50 Million in Private Placement Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, Into Clinical Development Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator dedicated to developing novel therapies for severe autoimmune and inflammatory disorders,…
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results, Advances Tecarfarin Clinical Development, and Strengthens Strategic Position in Anticoagulation Market Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company dedicated to developing next-generation anticoagulation therapies that address significant unmet needs in patient…
Rocket Pharmaceuticals Announces Second Quarter 2025 Results, Reshapes Strategic Focus Around Cardiovascular Gene Therapy Platform, and Advances Late-Stage Pipeline Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company developing a sustainable portfolio of genetic therapies for rare disorders…
Spine BioPharma Releases Phase 3 Data for SB-01 in Chronic Low Back Pain: Trial Misses Primary Endpoint Amid Strong Safety and Subgroup Efficacy Signals Spine BioPharma, Inc., a clinical-stage biopharmaceutical company advancing non-surgical treatments for spine-related pain, has announced topline…
Merck Completes €665 Million Divestment of Surface Solutions Business to GNMI, Marking Strategic Realignment Toward Innovation-Focused Growth In a decisive move underscoring its strategic emphasis on core technological and scientific capabilities, Merck, the global science and technology powerhouse headquartered in…
AeroRx Therapeutics Reports Positive Phase 2a Results for Inhaled AERO-007, the First Nebulized LABA/LAMA Combination Therapy in Development for COPD AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in proprietary nebulized combination therapies for chronic respiratory diseases, has announced encouraging…
KKR Acquires Majority Stake in HealthCare Royalty Partners, Expanding Life Sciences Strategy and Biopharma Royalty Capabilities KKR & Co. Inc., one of the world’s foremost investment firms, has announced a transformative acquisition: the majority ownership of HealthCare Royalty Partners (HCRx),…
Grifols Reports Strong First Half 2025 Results with Robust Revenue Growth, Rising Profitability, and Strategic Progress Across Business Units Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and a world leader in plasma-derived medicines, has announced a strong set of…
BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Early-Stage Lung Cancer, Expanding Its Role in Perioperative NSCLC Treatment BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to transforming cancer care through next-generation immunotherapy,…
MaaT Pharma Secures €37.5 Million EIB Loan to Propel Hemato-Oncology Pipeline and Microbiome Therapy Leadership MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotechnology company pioneering Microbiome Ecosystem Therapies™ (MET) to improve survival outcomes in cancer patients through immune modulation, announced a…